Form 4: Bicycle Therapeutics Director Receives Equity Awards

Bicycle Therapeutics PLC Director Alessandro Riva was granted 7,380 restricted share units and options to purchase 14,761 ordinary shares.

Summary

• Alessandro Riva, a Director of Bicycle Therapeutics PLC (BCYC), acquired 7,380 ordinary shares in the form of Restricted Share Units (RSUs) on January 2, 2026.
• Each RSU represents a contingent right to receive one ordinary share, with a reported acquisition price of $0.
• These RSUs are scheduled to vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Following this transaction, Alessandro Riva beneficially owns 19,880 ordinary shares directly.
• Additionally, Riva acquired stock options to purchase 14,761 ordinary shares on January 2, 2026, with an exercise price of $7.08 per share.
• These stock options also vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• The stock options have an expiration date of January 2, 2036.
• Following this transaction, Riva beneficially owns 14,761 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: This Form 4 filing is a routine disclosure of director compensation through equity awards. It is generally viewed as a neutral to slightly positive event as it aligns the director's interests with shareholders, but it does not contain information that would significantly alter the company's financial outlook or operational performance.

Positives

• The grant of restricted share units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for attracting and retaining qualified directors in the biotechnology industry.

Future Outlook

The filing indicates future vesting schedules for the granted restricted share units and stock options, with vesting occurring in four equal installments throughout 2026. The stock options have a long-term expiration date of January 2, 2036.

Industry Context

Equity grants, including restricted share units and stock options, are a common form of compensation for directors and executives in the biotechnology and pharmaceutical industries. This practice is designed to align the interests of company leadership with long-term shareholder value creation, particularly in sectors with long development cycles and significant R&D investment like biotech.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a standard practice across the biotechnology industry, comparable to compensation structures at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently utilize equity to incentivize leadership.
• The vesting schedule over a year is typical for such grants, ensuring continued commitment from the director.
• The exercise price of $7.08 for the options is set at the market price on the grant date, which is standard for incentive stock options.

Related Party Transactions

• The transaction involves the grant of equity awards to Alessandro Riva, a Director of Bicycle Therapeutics PLC, which constitutes a related party transaction as it is compensation to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with long-term shareholder value, potentially leading to more focused decision-making aimed at increasing share price.
• Employees: While not directly impacting all employees, such compensation structures for leadership can set a precedent for broader employee incentive programs.

Next Steps

• The restricted share units will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• The stock options will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.

Key Dates

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Restricted Share Units, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership